this article is not about her2 breast cancer only, but T-oligos work in such a way, they are likely to be effective in the majority of breast cancers independent of their subtype (ie all cells need telomeres to divide and these T-oligos utilize the shared mechanism of senescense--ageing--and induction of apoptosis (cell suicide) in response to DNA damage--which seem to be common to the majority of breast cancers.
http://breast-cancer-research.com/co...df/bcr1646.pdf